Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Vera Therapeutics, Inc.

Clinical trials sponsored by Vera Therapeutics, Inc., explained in plain language.

Vera Therapeutics, Inc. VERA NASDAQ

A clinical-stage biotechnology company developing treatments for autoimmune diseases, notably a monoclonal antibody for IgA nephropathy.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Not yet finished but already full! 3

New drug aims to calm immune attacks on kidneys

Disease control Recruiting now

This Phase 2 study tests atacicept, a drug that may reduce immune system attacks on the kidneys. About 250 adults with various autoimmune kidney diseases (like IgA nephropathy or membranous nephropathy) will receive weekly injections. Researchers will check safety and measure cha…

Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control

Last updated Jun 28, 2026 00:00 UTC